About EpiCypher
EpiCypher is a Healthcare company based in Chapel Hill (United States) founded in 2012. Epigenetic kits, reagents, and assays are supplied for research applications. EpiCypher has raised $3.43 million across 45 funding rounds from investors including HHS. Its website epicypher.com draws about 28 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Epigenetics. Its legal entity is EPICYPHER INC. Its competitors include Inherent Biosciences, Active Motif and Genpathway.
Company details
EpiCypher was founded in 2012 and is based in Chapel Hill, United States. Operations focus on the epigenetics sector, where kits, reagents, and assays are developed for research use. Products offered include antibodies, cell extracts, histone peptide arrays, histone peptides, nucleosomes, peptide synthesis services, and recombinant proteins. Cutana CUTRUN assays are also provided as an alternative to ChIP assays, enabling reduced cell input and broader target profiling.
- Headquarters Chapel Hill, United States
- SectorsHealthcare
- Email••••••••
- Website epicypher.com
- Social LinkedIn X Facebook YouTube
- Legal Name Epicypher Inc
- Total Equity Funding$3.43M (USD)
in 45 rounds
- Latest Funding Round$1.27M (USD), Grant
Sep 2024
- Investors
Apps and channels of EpiCypher
its YouTube channel EpiCypher Videos has 382 subscribers and 26 videos.
Videos from EpiCypher
The most watched videos on EpiCypher's YouTube channel, EpiCypher Videos (382 subscribers). Click a video to play it here.
More on EpiCypher Videos.
Funding Insights of EpiCypher
EpiCypher has successfully raised a total of $3.43M across 45 strategic funding rounds. The most recent funding activity was a Grant round of $1.27 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.43M
- Total Rounds 45
- Last Round Grant — $1.27M
- First Round $35,300
(Apr 2013)
- Investors Count 1
Latest 10 of 45 funding rounds of EpiCypher with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $1.27M | Grant | – | – | |
| Aug 2024 | $1.27M | Grant | – | – | |
| Jun 2024 | $3.3M | Series A | – | – | – |
| Mar 2024 | $1.27M | Grant | – | – | |
| Jul 2023 | $2.02M | Grant | – | – | |
| Jul 2023 | $406,374 | Grant | – | – | |
| Jun 2023 | $2.55M | Grant | – | – | |
| May 2023 | $1.43M | Grant | – | – | |
| Mar 2023 | $2.01M | Grant | – | – | |
| Sep 2022 | $326,506 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in EpiCypher
EpiCypher has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for EpiCypher
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EpiCypher
32 people are tracked at EpiCypher (12 in leadership, 4 in board & advisors, 16 in team).
| Name | Role | Group |
|---|---|---|
Michael-Christopher Keogh | Chief Scientific Officer | Leadership |
Zu-Wen Sun | VP, Product Development | Leadership |
Marcus Cheek | Director Of Synthetic And Structural Biochemistry (chemistry) | Leadership |
Matt Meiners | Senior Director of Production | Leadership |
Martis Cowles | Chief Business Officer | Leadership |
Danielle Remmy | Director of Commercial Operations | Leadership |
Keith Maier | Associate Director Of Product Development | Leadership |
Matthew Marunde | Associate Director, Automation | Leadership |
James Bone | President & Co-founder | Leadership |
Andrea Johnstone | Senior Director of Product Development | Leadership |
Mark Kaderli | Senior Director of Sales | Leadership |
Bryan Venters | Senior Director Of Genomic Technologies | Leadership |
Mark Bedford | Director | Board & advisors |
Or Gozani | Director | Board & advisors |
Brian Strahl | Director | Board & advisors |
Joe McMahon | Director | Board & advisors |
Courtney Barnes | Research Associate II | Team |
Sabrina Hunt, Ph.D. | Research Scientist II | Team |
Cheryl S. | Project Manager | Team |
Victoria Hsiung | Associate Product Manager | Team |
12 more people are available in the full profile.
Complete people profiles for EpiCypher
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EpiCypher
3 dated milestones of EpiCypher across 12 years, from founding to its latest funding, stage changes and deals.
- Founded EpiCypher is founded.
- Funding First funding round of $35K.
- Funding Latest funding round, Grant, of $1.3M.
Competitors of EpiCypher
EpiCypher has 3 listed competitors in our database. They include Inherent Biosciences, Active Motif and Genpathway.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inherentbio.com | 2019 | Salt Lake, United States | Epigenetic diagnostics and therapeutics for complex diseases are developed. | |||
| activemotif.com | 1999 | Carlsbad, United States | Epigenetics and gene regulation research tools are developed and distributed. | |||
| genpathway.com | 1999 | Carlsbad, United States | Systems biology company specializing in genome-wide epigenetic studies |
Detailed competitors of EpiCypher
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EpiCypher
The website of EpiCypher (epicypher.com) receives about 27.7K visits a month.
- Monthly visits27.7K
▲ 10% vs previous month
Websites whose visitors overlap most with EpiCypher. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| activemotif.com | 100% | 57.6K | #613,526 | View details | |
fusion-conferences.com | fusion-conferences.com | 82% | #2,023,731 | – | |
activemotif.jp | activemotif.jp | 80% | #3,495,725 | – | |
| pluto.bio | 78% | 15.2K | #1,637,525 | View details | |
rnasociety.org | rnasociety.org | 76% | #1,221,925 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 34 similar websites and full traffic analytics for EpiCypher
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 34 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as EpiCypher (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epicypher
Complete news archive for EpiCypher
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EpiCypher
EpiCypher was founded in 2012 and raised its 1st funding round 1 year after it was founded.
EpiCypher is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.
EpiCypher is a funded company, having raised a total of $3.43M across 45 funding rounds to date. The company's 1st funding round was a Grant of $326.51K, raised on Apr 2013.
EpiCypher was founded in 2012 and is based in Chapel Hill, United States. Operations focus on the epigenetics sector, where kits, reagents, and assays are developed for research use. Products offered include antibodies, cell extracts, histone peptide arrays, histone peptides, nucleosomes, peptide synthesis services, and recombinant proteins. Cutana CUTRUN assays are also provided as an alternative to ChIP assays, enabling reduced cell input and broader target profiling.
EpiCypher's top competitors include Inherent Biosciences, Active Motif and Genpathway.
EpiCypher has 1 investor. Key investors include HHS.
EpiCypher operates through Epicypher Inc.